Sounds great in theory, but not as easy as it sounds.
ALL IMO, the largest economic cost and biggest risk to IHL would be building the sales & marketing infrastructure channel to take product to market. One of the biggest moats of BP is their sales and marketing channels. Can you imagine the annual ongoing cost of all those people? This is why small discovery companies sell their solutions to BP.
There are only two realistic options; 1) sell a complete solution to BP or 2) Licence the solution to BP. Big Pharma's can have the whip hand in these negotiations and would typically opt for buying the complete solution to keep control and own the solution. They are not going to be too interested in licencing unless there is further development options with the one compound that they don't want to pay for...
Either way should be a reasonable rerate of the SP
GLTAH
IHL Price at posting:
19.3¢ Sentiment: Hold Disclosure: Held
